A Phase 1/2 interventional study of Carfilzomib and Carboplatin in Extensive-Stage Small-Cell Lung Cancer, sponsored by Amgen. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 25th largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 1/2, and was the 14th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 4
First in 1998; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 48 across the 36 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
19 studies in Small Cell Lung Carcinoma by Amgen: 4 open now, 12 under way, 5 of them phase 3. Of 5 finished, 4 (80%) have results posted.
Among the 19 studies in Small Cell Lung Carcinoma by Amgen, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2013, is one of 2 in phase 1/2, and was the 4th registered.
Amgen’s Small Cell Lung Carcinoma studies by the year they started, since 2002.
4 of the studies testing carboplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856695Intergroupe Francophone de Cancerologie ThoraciqueDurvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | 2026-11 |
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
| NCT06830694Sehhoon ParkClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | 2027-03-31 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 19 in Small Cell Lung Carcinoma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
Drug: Carfilzomib · Drug: Carboplatin · Drug: Etoposide
Administered by intravenous infusion.
Also known as: PR-171, PR171, Kyprolis®
Administered by intravenous infusion.
Administered by intravenous infusion.
Number of Participants With Dose-limiting Toxicities
The maximum tolerated dose (MTD) was defined as the highest dose level at which \< 33% of participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle. Dose-limiting toxicities were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. A DLT was defined as: * A grade 3 or greater non-hematologic toxicity that was assessed as related to carfilzomib by the investigator except in the case of neuropathy. A grade 2 or higher neuropathy with pain was considered a DLT. * Grade 4 neutropenia: absolute neutrophil count (ANC) \< 500 mm³, lasting ≥ 7 days despite granulocyte colony stimulating factor support, or any febrile (temperature \> 38.3°C) neutropenia (ANC \< 1000 mm³). * Thrombocytopenia of any grade associated with clinically significant bleeding or platelet/blood transfusion * Grade 4 fatigue lasting ≥ 7 days * Grade 3 nausea, vomiting or diarrhea lasting ≥ 7 days.
Time frame: First 21-day Cycle
Number of Participants With Adverse Events (AEs)
The severity of each adverse event was assessed using the NCI-CTCAE Version 4.03 according to the following: Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4 - Life-threatening Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
Time frame: From first day of any study treatment (i.e., carfilzomib, carboplatin, or etoposide) up to 30 days after the last day of study treatment. The median overall duration of treatment was 16 weeks.
Overall Survival (OS) - Phase 2
Overall Survival (OS) is defined as the time from randomization to the date of death. Overall survival was a specified secondary endpoint for the phase 2 portion of the study; since phase 2was not conducted, OS was not analyzed.
Time frame: 30 months
Maximum Plasma Concentration - Phase 2
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
Time frame: Cycle 1 Day 2
Time of Maximum Plasma Concentration - Phase 2
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
Time frame: Cycle 1 Day 2
Area Under Plasma Concentration-Time Curve - Phase 2
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
Time frame: Cycle 1 Day 2
Progression-free Survival
Progression-free survival (PFS) was specified as a primary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed PFS was analyzed in phase 1b participants on an exploratory basis. PFS was defined as the time from the start of treatment to documented disease progression or death due to any cause, whichever occurred first. Disease progression was determined by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, defined as at least a 20% increase in the size of target lesions (absolute increase ≥ 5 mm), unequivocal progression of existing non-target lesions, or any new lesions. Median PFS was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored.
Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
Overall Response Rate
The overall response rate (ORR) was defined as the percentage of participants for whom the best overall confirmed response was either complete response (CR) or partial response (PR) assessed by the investigator according to RECIST v1.1 criteria. CR: Disappearance of all target and non-target lesions, no new lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters, or, the disappearance of all target lesions and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.
Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
Duration of Response
Duration of response (DOR) was calculated for participants who achieved a confirmed CR or PR. defined as the time from first evidence of confirmed PR/CR to disease progression or death due to any cause. Median DOR was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored. DOR was originally specified as a secondary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed, DOR was analyzed in phase 1b participants on an exploratory basis.
Time frame: From first dose of study drug until the end of treatment; median duration of treatment was 16 weeks.
This study was conducted at 17 centers in the United States, Russia, and Canada.
| Milestone | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² |
|---|---|---|---|---|---|
| Started | 5 | 3 | 3 | 15 | 6 |
| Completed | 5 | 3 | 3 | 14 | 6 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing in study | 0 | 0 | 0 | 1 | 0 |
The maximum tolerated dose (MTD) was defined as the highest dose level at which \< 33% of participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle. Dose-limiting toxicities were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03. A DLT was defined as: * A grade 3 or greater non-hematologic toxicity that was assessed as related to carfilzomib by the investigator except in the case of neuropathy. A grade 2 or higher neuropathy with pain was considered a DLT. * Grade 4 neutropenia: absolute neutrophil count (ANC) \< 500 mm³, lasting ≥ 7 days despite granulocyte colony stimulating factor support, or any febrile (temperature \> 38.3°C) neutropenia (ANC \< 1000 mm³). * Thrombocytopenia of any grade associated with clinically significant bleeding or platelet/blood transfusion * Grade 4 fatigue lasting ≥ 7 days * Grade 3 nausea, vomiting or diarrhea lasting ≥ 7 days.
| Participants | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities | 0 | 0 | 0 | 0 | 1 |
The severity of each adverse event was assessed using the NCI-CTCAE Version 4.03 according to the following: Grade 1 - Mild: Asymptomatic or mild symptoms; intervention not indicated Grade 2 - Moderate: Minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3 - Severe: Medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4 - Life-threatening Grade 5 - Fatal. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
| Participants | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² |
|---|---|---|---|---|---|
| Any adverse event | 5 | 3 | 3 | 15 | 5 |
| Adverse events ≥ grade 3 | 3 | 3 | 2 | 13 | 4 |
| Serious adverse events | 1 | 1 | 1 | 7 | 2 |
| AEs leading to disocontinuation of study drug | 1 | 0 | 0 | 3 | 1 |
| Fatal adverse events | 0 | 0 | 0 | 0 | 1 |
Overall Survival (OS) is defined as the time from randomization to the date of death. Overall survival was a specified secondary endpoint for the phase 2 portion of the study; since phase 2was not conducted, OS was not analyzed.
No measurements were reported for this outcome.
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
No measurements were reported for this outcome.
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
No measurements were reported for this outcome.
Pharmacokinetic (PK) analyses were specified as secondary endpoints for the phase 2 portion of the study; since phase 2 was not conducted, PK analyses were not performed.
No measurements were reported for this outcome.
Progression-free survival (PFS) was specified as a primary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed PFS was analyzed in phase 1b participants on an exploratory basis. PFS was defined as the time from the start of treatment to documented disease progression or death due to any cause, whichever occurred first. Disease progression was determined by the investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, defined as at least a 20% increase in the size of target lesions (absolute increase ≥ 5 mm), unequivocal progression of existing non-target lesions, or any new lesions. Median PFS was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored.
| months | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | All Participants |
|---|---|---|---|---|---|---|
| Progression-free Survival | 4.0 (2.8 to 6.7) | 6.4 (6.2 to 6.8) | 7.0 (4.0 to 7.0) | 2.9 (2.5 to 5.4) | 3.8 (1.1 to 6.3) | 4.4 (2.8 to 5.6) |
The overall response rate (ORR) was defined as the percentage of participants for whom the best overall confirmed response was either complete response (CR) or partial response (PR) assessed by the investigator according to RECIST v1.1 criteria. CR: Disappearance of all target and non-target lesions, no new lesions and normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters, or, the disappearance of all target lesions and persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above normal limits.
| percentage of participants | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | All Participants |
|---|---|---|---|---|---|---|
| Overall Response Rate | 60.0 (14.7 to 94.7) | 100.0 (29.2 to 100.0) | 66.7 (9.4 to 99.2) | 33.3 (11.8 to 61.6) | 33.3 (4.3 to 77.7) | 46.9 (29.1 to 65.3) |
Duration of response (DOR) was calculated for participants who achieved a confirmed CR or PR. defined as the time from first evidence of confirmed PR/CR to disease progression or death due to any cause. Median DOR was calculated using Kaplan-Meier methods. Participants with no baseline disease assessments, who started a new anticancer therapy before documentation of PD or death, with death or PD immediately after more than 1 consecutively missed disease assessment visit or alive without documentation of PD before the data cutoff date were censored. DOR was originally specified as a secondary endpoint for the phase 2 portion of the study. Since phase 2 did not proceed, DOR was analyzed in phase 1b participants on an exploratory basis.
| months | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | All Participants |
|---|---|---|---|---|---|---|
| Duration of Response | 4.9 (2.8 to 5.4) | 5.0 (4.7 to 5.6) | NA (2.8 to NA) | 4.3 (1.6 to NA) | 4.5 (4.2 to 4.8) | 4.8 (2.8 to 5.4) |
Collected over From first day of any study treatment (i.e., carfilzomib, carboplatin, or etoposide), and within 30 days of the last day of study treatment. The median overall duration of treatment was 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carfilzomib 20/20 mg/m² | — | 1/5 (20%) | 5/5 (100%) |
| Carfilzomib 20/27 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| Carfilzomib 20/36 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| Carfilzomib 20/45 mg/m² | — | 7/15 (46.7%) | 15/15 (100%) |
| Carfilzomib 20/56 mg/m² | — | 2/6 (33.3%) | 5/6 (83.3%) |
| Event | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/5 | 0/3 | 1/3 | 2/15 | 0/6 |
| Clostridium difficile colitisInfections and infestations | 0/5 | 0/3 | 1/3 | 0/15 | 0/6 |
| PneumoniaInfections and infestations | 0/5 | 1/3 | 0/3 | 1/15 | 1/6 |
| Fluid overloadMetabolism and nutrition disorders | 0/5 | 1/3 | 0/3 | 0/15 | 0/6 |
| Cerebrovascular accidentNervous system disorders | 1/5 | 0/3 | 0/3 | 0/15 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 0/5 | 0/3 | 0/3 | 0/15 | 1/6 |
| Atrial fibrillationCardiac disorders | 0/5 | 0/3 | 0/3 | 0/15 | 1/6 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/3 | 0/15 | 1/6 |
| Injection site abscessInfections and infestations | 0/5 | 0/3 | 0/3 | 1/15 | 0/6 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/5 | 0/3 | 0/3 | 1/15 | 0/6 |
| Event | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/5 | 3/3 | 2/3 | 8/15 | 3/6 |
| NauseaGastrointestinal disorders | 3/5 | 3/3 | 3/3 | 5/15 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 1/5 | 2/3 | 0/3 | 10/15 | 3/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/5 | 2/3 | 1/3 | 7/15 | 4/6 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 2/3 | 1/3 | 5/15 | 0/6 |
| Neutrophil count decreasedInvestigations | 1/5 | 2/3 | 0/3 | 0/15 | 1/6 |
| Platelet count decreasedInvestigations | 0/5 | 2/3 | 0/3 | 2/15 | 2/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/5 | 0/3 | 2/3 | 2/15 | 1/6 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/5 | 2/3 | 0/3 | 0/15 | 1/6 |
| HyponatraemiaMetabolism and nutrition disorders | 0/5 | 2/3 | 1/3 | 0/15 | 1/6 |
| Age, Continuous(years) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| Mean | 69.2 ± 13.8 | 62.3 ± 8.5 | 59.0 ± 7.5 | 56.9 ± 9.4 | 58.8 ± 7.9 | 59.9 ± 10.1 |
| Age, Customized(Participants) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| < 65 years | 2 | 2 | 2 | 14 | 5 | 25 |
| ≥ 65 years | 3 | 1 | 1 | 1 | 1 | 7 |
| Sex: Female, Male(Participants) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 2 | 1 | 5 | 1 | 12 |
| Male | 2 | 1 | 2 | 10 | 5 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 3 | 3 | 14 | 5 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| White | 5 | 3 | 3 | 14 | 6 | 31 |
| Other | 0 | 0 | 0 | 1 | 0 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Carfilzomib 20/20 mg/m² | Carfilzomib 20/27 mg/m² | Carfilzomib 20/36 mg/m² | Carfilzomib 20/45 mg/m² | Carfilzomib 20/56 mg/m² | Total |
|---|---|---|---|---|---|---|
| 0 (Fully active) | 4 | 0 | 1 | 3 | 2 | 10 |
| 1 (Restrictive but ambulatory) | 1 | 3 | 2 | 12 | 4 | 22 |
The record gives a start of Nov 2013, a primary completion of Aug 2016 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carfilzomib · Carboplatin · Etoposide